Summary

Venous thrombosis, which manifests mainly as deep vein thrombosis (DVT) and pulmonary embolism (PE), is a common and serious disorder; it occurs in 1 per 1000 individuals per year worldwide, and patients who suffer from DVT or PE are at risk of recurrent events [Rosendaal FR. PLoS Med 2012]. There is limited information on safe and effective long-term preventive strategies. This article discusses results from the Aspirin to Prevent Recurrent Venous Thromboembolism [ASPIRE; ACTRN12605000004662] trial.